

Proteq West Nile (--)- Suspension for injection

Authorised

- Canarypox virus, strain vCP2017, expressing preM and E proteins genes of West Nile virus, Live

Product identification

Medicine name:

Proteq West Nile (--)- Suspension for injection

Active substance:

Canarypox virus, strain vCP2017, expressing preM and E proteins genes of West Nile virus, Live

Target species:

Horse

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Canarypox virus, strain vCP2017, expressing preM and E proteins genes of West Nile virus, Live

Presentation_strength: $6.0 \leq R \leq 7.8 \log_{10}$ CCID₅₀ Reference: Hse Comments: Supply of antigen Index: 0

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:**Intramuscular use:**

-

Horse

- Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI05AX

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Belgium , France , Germany , Luxembourg , Spain

Package description:

Packaging:Vial (glass), Package_size:10 vials, Content:1 ml (1 dose)

Packaging:Vial (glass), Package_size:5 vials, Content:1 ml (1 dose)

Packaging:Vial (glass), Package_size:2 vials, Content:1 ml (1 dose)

Packaging:Vial (glass), Package_size:1 vial, Content:1 ml (1 dose)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:

5/08/2011

Manufacturing sites for batch release:

Boehringer Ingelheim Animal Health France

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

5/08/2011

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 11/07/2023

[Download](#)

ema-puar-proteq-west-nile-v-2005-par-en.pdf